- Home
- BZUN vs ABOS Comparison
BZUN vs ABOS Comparison
Compare BZUN & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- ABOS
- Stock Information
- Founded
- BZUN 2007
- ABOS 1996
- Country
- BZUN China
- ABOS United States
- Employees
- BZUN N/A
- ABOS N/A
- Industry
- BZUN Catalog/Specialty Distribution
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- ABOS Health Care
- Exchange
- BZUN Nasdaq
- ABOS Nasdaq
- Market Cap
- BZUN 166.3M
- ABOS 166.4M
- IPO Year
- BZUN N/A
- ABOS 2021
- Fundamental
- Price
- BZUN $2.56
- ABOS $2.55
- Analyst Decision
- BZUN Buy
- ABOS Strong Buy
- Analyst Count
- BZUN 2
- ABOS 4
- Target Price
- BZUN $2.20
- ABOS $9.00
- AVG Volume (30 Days)
- BZUN 217.7K
- ABOS 166.4K
- Earning Date
- BZUN 08-28-2024
- ABOS 11-11-2024
- Dividend Yield
- BZUN N/A
- ABOS N/A
- EPS Growth
- BZUN N/A
- ABOS N/A
- EPS
- BZUN N/A
- ABOS N/A
- Revenue
- BZUN $1,235,027,314.00
- ABOS N/A
- Revenue This Year
- BZUN $5.22
- ABOS N/A
- Revenue Next Year
- BZUN $5.32
- ABOS N/A
- P/E Ratio
- BZUN N/A
- ABOS N/A
- Revenue Growth
- BZUN 5.56
- ABOS N/A
- 52 Week Low
- BZUN $1.90
- ABOS $1.81
- 52 Week High
- BZUN $3.51
- ABOS $5.46
- Technical
- Relative Strength Index (RSI)
- BZUN 63.75
- ABOS 46.61
- Support Level
- BZUN $2.23
- ABOS $2.15
- Resistance Level
- BZUN $2.49
- ABOS $2.65
- Average True Range (ATR)
- BZUN 0.11
- ABOS 0.15
- MACD
- BZUN 0.03
- ABOS 0.01
- Stochastic Oscillator
- BZUN 95.35
- ABOS 50.51
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.